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Urine glycosaminoglycans in congenital and acquired nephrotic syn-
drome. To evaluate the specificity of a raised heparan sulphate (HS)
excretion previously reported in four children with congenital nephrotic
syndrome (CNS), we measured the urinary excretion of HS and
chondroitin sulphate (CS) in seven children with Finnish-type congen-
ital nephrotic syndrome (CNSF), seven with diffuse mesangial sclerosis
(DMS), nine with focal segmental glomerulosclerosis (FSGS), 14 with
steroid-sensitive nephrotic syndrome of whom eight had a biopsy
confirming minimal change histology (SSNS), and 17 controls. The
urine HS/CS ratio in normal children had a median of 0.36 (observed
range 0.21 to 0.68) and was independent of age. HS/CS ratio was
significantly greater than controls in CNSF (median 0.80, range 0.43 to
1.28), DMS (median 0.81, range 0.49 to 1.13) and FSGS children
(median 0.66, range 0.38 to 1.6), but was not in SSNS (median 0.44,
range 0.28 to 0.70). There was a positive correlation between the HS/CS
ratio and urine albumin excretion. High HS/CS ratios are not diagnostic
of a particular histological variety of CNS.
Research on the pathogenesis of proteinuria in renal disease
has focused on alterations in the charge and size filtration
characteristics of the glomerular basement membrane (GBM)
[1—6]. Much of this work has centered around the components
of the GBM that are responsible for its charge [7—12]. Heparan
sulphate (HS), a proteoglycan found predominantly in the
lamina rarae of the GBM [11], is the major component of the
fixed anionic charge in the GBM [4, 9, 11]. There is also
evidence that other anionic groups, such as carboxyl residues
linked to GBM glycoproteins, are important [10]. The contri-
bution to the charge barrier of other glycoproteins such as
chondroitin sulphate (CS) is less clear [7—9].
Vernier et al reported that the concentration of anionic sites
in the GBM was decreased in children with congenital nephrotic
syndrome (CNS) [4]. In their study the cationic probe polyeth-
yleneimine (PEI) was used to identify anionic sites, and normal
kidney tissue was incubated with heparatinase to demonstrate
that HS was indeed the major anionic group labelled by PEI in
the GBM. Vermylen et al [5] found a marked reduction in the
GBM content of HS in a child with CNS histologically charac-
terized as diffuse mesangial sclerosis (DMS). They also found
an increased excretion of HS relative to CS in the urine of this
case and three other children with CNS, two of whom had
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Finnish-type histology (CNSF) and the third DMS. They sug-
gested that the basic defect was a failure to incorporate HS into
the macromolecular structure of the GBM with subsequent loss
of HS into the urine.
The purpose of the present study was to investigate HS and
CS excretion in children with various forms of CNS together
with age-matched controls and children with later onset, ac-
quired nephrotic syndrome. In particular, we wanted to find out
whether an increased urine HS/CS ratio was specific for a
particular form of CNS.
Methods
Patients
Twenty-three children with early onset NS were studied:
seven with CNSF, seven with DMS, nine children with focal
glomerulosclerosis (FSGS), three of whom were under six
months of age and all steroid resistant. None were on steroids
at the time of study. Fourteen children with acquired steroid-
sensitive nephrotic syndrome (SSNS) were studied, 10 of whom
were receiving steroids at the time of study, at doses ranging
from 0.05 mg/kg alternate day to 2 mg/kg/day. Eight had biopsy
evidence confirming minimal change histology. The controls
consisted of 17 normal children who either attended the hospital
creche or were the children of laboratory staff.
Methods
Random urine samples were collected with merthiolate
1:10,000 as preservative, coded, and stored at —70°C until
analyzed. The code was not broken until the end of the study.
Urinary glycosaminoglycans (GAGs) were isolated with the
cationic dye Alcian Blue as described by Whiteman [13]. Alcian
Blue in a 0.05% solution in 50 m sodium acetate buffer pH 5.8
with 50 m magnesium chloride has been shown to precipitate
GAGs specifically [13]. The Alcian Blue used was from Impenal
Chemical Industries Ltd. Two milliliters of centrifuged urine
was added to 20 ml of the Alcian Blue solution. The resulting
GAG precipitate was dissociated with 0.2 ml 4 M sodium
chloride solution and 0.1 ml methanol. The Alcian Blue was
denatured by alkalinizing the mixture with 0.1 ml 0.1 M sodium
carbonate and 0.4 ml water, and separated by centrifugation.
The GAGs were precipitated from the remaining mixture by the
addition of 3 volumes of ethanol and subsequent centrifugation.
The supernatant was discarded, the GAGs were dried overnight
at room temperature, and dissolved in 20 j.d water. Aliquots of
0.5 or 1.0 .d were applied to a cellulose acetate strip adjacent to
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Controls(N = 17)
Age at
study
years
UA/UC HS/CR CS/CR
mg/mg HS/CS
Median 1.9 0.04 0.08 0.23 0.36
Observed range 0.4-9,1 0.00-0.10 0.03-0.32 0.06-0.88 0.21-0.68
standards containing both HS and CS at concentrations ranging
from 0.12 mg/mI to 0.75 mg/mi. Electrophoresis was performed
in 0.1 M barium acetate pH 6.0 for three hours with a current of
7.5 volts/cm. The individual GAGs separated into discrete
bands which were visualized by staining with the Alcian Blue
reagent. Excess Alcian Blue was removed by washing with a
solution containing 50 mM magnesium chloride and 50 mrs
sodium acetate. The individual bands were cut out and eluted
with I ml of a dimethyl suiphoxide reagent, which was prepared
by dissolving 0.51 G anhydrous sodium acetate, 1.27 g
MgCI2. 6H20 and 1.56 ml glacial acetic acid in 250 dimethyl
suiphoxide (Sigma Chemicals Ltd, spectroscopic grade). The
optical density was read at 678 nm. A standard curve was
obtained from the standards which were run on the same
cellulose acetate strip. The recovery following GAG precipita-
tion and extraction was 54% for HS and 62% for CS. The
within-assay coefficient of variation was 7% for HS and 9% for
CS, and the between-assay reproducibility of the HS/CS ratio
was 13%.
The urinary albumin concentration was measured by a single
radial immunodiffusion assay [14]. A 2% solution of anti-human
albumin antibody (RaHu/AIb Ref 3283, Nordic, Tilburg, Neth-
erlands) in 1.5% agarose gel was used and the concentrations of
the samples were calculated by reference to commercial stan-
dards (Sigma Chemicals Ltd). Urine creatinine concentration
was measured using a Beckman analyzer utilizing the Jaffé
reaction, and results were expressed as the urinary albumin!
creatinine ratio (Alb/Cr, mg/mg).
The Mann-Whitney test and the Spearman rank correlation
coefficient test were used in the statistical analysis.
Fig. 1. The urinary heparan sulphate!
— chondroizin sulphate ratio in normal
10 children—no significant relationship with age(r = 0.39, p > 0.1).
Results
The urinary heparan sulphate/creatinine (HS/Cr) ratio (Table
1) in the 17 control children had a median of 0.08, observed
range 0.03 to 0.32 mg/mg, and the chondroitin sulphate/creati-
nine (CS/Cr) ratio had a median 0.23, range 0.06 to 0.88 mg/mg.
The urinary HS/CS ratio had a median of 0.36, range 0.21 to
0.68 mg/mg. Both HS/Cr and CS/Cr decreased with age, but
HS/CS did not (r = 0.39, P > 0.1) (Fig. 1).
The HS/CS ratios (Table 2) in the CNSF, DMS and FSGS
groups were all significantly greater than the control values, but
that for SSNS was not (CNSF median: 0.80, range 0.43 to 1.28,
P < 0.001; DMS median: 0.81, range 0.49 to 1.13, P < 0.0005;
FSGS median: 0.66, range 0.38 to 1.6, P <0.01; SSNS median:
0.44, range 0.28 to 0.70, P > 0.05. There was no difference in
the HS/CS ratio within the SSNS group, between those children
with confirmed MCNS histology and those without histology
(Table 2, Fig. 2).
The HS/Cr ratio in both CNSF and DMS was greater than in
controls, although it only reached significance level in the
CNSF group (P < 0.005). However, there was no significant
difference between the CS/Cr ratio in the controls and the
CNSF, DMS and FSGS groups, indicating that the raised
HS/CS ratio is due to an elevation in urine HS concentration
rather than a decrease in the CS concentration (Table 2).
The HS/CS ratio in the CNSF, DMS, FSGS and SSNS
groups was strongly correlated with the urine Alb/Cr (r = 0.66,
P < 0.0001) (Fig. 3). However, Alb/Cr in the SSNS group was
significantly lower than that in the CNSF, DMS or FSGS
groups (P < 0.001), but the correlation between HS/CS and
Alb/Cr persisted even when SSNS patients were excluded from
the regression analysis (r = 0.45, P < 0.05).
There was no correlation between HS/CS and plasma creat-
mine concentration, nor were there any differences in plasma
creatinine concentration between any of the nephrotic sub-
groups studied.
Discussion
The observation of Vermylen et al [5] of increased HS
excretion in the urine of four children with CNS was of interest
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Table 1. Urinary GAG excretion in normal controls
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Table 2. Urinary GAG excretion in CNSF, DMS, FSGS and SSNS
Age at Age at
diagnosis study PCR
Pt Sex Histology years pmo1/!iter
UA/UC HS/CR CS/CR
mg/mg HS/CS
Congenital nephrotic syndrome Finnish-type
M CNSF <0.1 0.9 141 89.0 0.33 0.26 1.30
2 M CNSF <0.1 1.8 42 158.1 0.06 0.06 1.00
3 F CNSF <0.1 0.8 NA 19.7 0.25 0.58 0.42
4 M CNSF <0.1 1.09 NA 27.4 0.10 0.10 0.81
5 M CNSF <0.1 0.32 32 57.9 0.13 0.13 1.00
6 F CNSF <0.1 0.11 40 1.5 0.37 0.95 0.47
7 M CNSF <0.1 0.35 35 11.7 0.25 0.32 0.81
median <0.1 0.80 40 27.4c 0.17 0.26 080b
range 0.11-1.80 32-141 1.50-158.1 0.06-0.37 0.06-0.95 0.42-1.30
Diffuse mesangial sclerosis
8 M DMS 0.1 0.13 14 107.9 0.50 0.51 1.06
9 M DMS 0.1 0.52 36 8.7 0.08 0.09 0.81
10 M DMS 0.8 0.91 268 19.2 0.07 0.15 0.49
11 M DMS 0.4 0.83 40 101.8 0.17 0.23 0.76
12 M DMS <0.1 1.22 31 15.8 0.08 0.08 0.99
13 M DMS 0.4 0.72 73 6.8 0.37 0.33 1.13
14 M DMS 0.3 1.90 230 5.6 0.16 0.29 0.58
median 0.3 0.83 57 15,8c 0.16 0.23 0.81c
range <0.1-0.8 0.13-1.90 14-268 5.6-107.9 0.07-0.50 0.08-0.51 0.49-1.13
Focal glomerulosclerosis
15 M FSGS 0.3 2.2 39 30.0 0.19 0.30 0.57
16 M FSGS 0.4 0.9 87 26.0 0.06 0.12 0.50
17 M FSGS 0.7 1.4 21 16.2 0.63 0.96 0.66
18 M FSGS 1.9 2.3 50 25.6 0.04 0.05 0.80
19 M FSGS 1.2 2.8 34 4.0 0.07 0.17 0.43
20 F FSGS 2.7 3.8 175 37.5 0.48 0.30 1.60
21 F FSGS 2.5 7.7 51 1.6 0.04 0.10 0.40
22 F FSGS 1.3 8.4 63 3.8 0.07 0.10 0.70
23 M FSGS 0.6 14.8 105 10.1 0.36 0.32 1.13
median 1.2 2.8 51 16,lc 0.07 0.17 O.66a
range 0.3-2.7 0.9-14.8 21-175 1.6-37.5 0.04-0.63 0.05-0.96 0.38-1.60
Age at Age at
diagnosis study PCR UA/UC
Pt Sex Histology years p.mo!/liter
HS/CR CS/CR
HS/CS
Steroid dose
mg/kgmg/mg
Steroid sensitive nephrotic syndrome
24 M MCNS 2.1 10.7 51 3.6 0.06 0.15 0.40 0.5 alt day
25 M MCNS 2.5 3.6 34 3.2 0.09 0.24 0.38 2.0 daily
26 M MCNS 10.4 15.3 67 1.2 0.05 0.07 0.71 0.9 alt day
27 M MCNS 1.6 16.4 61 4.9 0.04 0.07 0.59 1.0 daily
28 M MCNS 1.5 7.0 44 8.4 0.02 0.04 0.45 no steroids
29 M MCNS 1.5 12.4 96 2.9 0.03 0.06 0.44 0,7 daily
30 M MCNS 1.5 9.7 NA 3.0 0.02 0.04 0.49 no steroids
31 M MCNS 7.6 17.7 58 3.6 0.02 0.04 0.47 no steroids
32 M NA 1.3 8.0 42 2.7 0.10 0.30 0.32 0.8 alt day
33 F NA 2.5 6.6 46 6.4 0.03 0.06 0.52 0.05 alt day
34 M NA 4.6 11.0 52 9.9 0.04 0.08 0.50 no steroids
35 M NA 1.9 10.3 37 1.1 0.04 0.11 0.34 0.05 alt day
36 M NA 1.7 3.7 53 1.8 0.07 0.2 0.32 0.38 alt day
37 F NA 1.4 4.9 45 2.2 0.15 0.24 0.58 0.70 alt day
median 1.8 10.3 51 3.2c 0.04 0.08 0.46"
range 1.3-10.4 3.6-17.7 34-96 1.1-9.9 0.02-0.15 0.04-0.30 0.32-0.71
Abbreviations are: NA = not available, alt = alternate
ap < 0.01, bp < 0.001, p < 0,0005, dNot significant
when taken in the context of the virtual absence of HS in the
GBM of one them, suggesting failure of incorporation of HS
into the GBM. We investigated children with different forms of
congenital nephrotic syndrome in order to ascertain whether
abnormalities of the HS/CS ratio were characteristic of a
particular type of CNS. It also prompted the speculation that
urinary HS measurement might be of diagnostic value in the
assessment of CNS.
We refined the quantitative assay for HS and CS in urine used
previously [5], introducing separate standard curves in each
analysis. The reaction for this was the observation of non-
linearity at high concentrations of GAGs. Moreover, Alcian
1.8
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Controls CNSF DMS
Blue precipitates other macromolecules such as Tamm-Horsfall
protein, and therefore the calculation of individual GAG con-
centration from the total GAG measurement and the HS/CS
optical density ratio, as in the previous study, is less accurate
than direct measurement.
We elected to study the urinary HS/CS ratio. The use of
HS/Cr would have been unreliable as the urinary creatinine
excretion may be low in children in poor nutritional state. It
would have led to artificially elevated values, especially in the
CNSF group. In addition, we observed that the HSICS ratio is
independent of age.
Our results, based on a larger sample of patients, confirm
Vermylen et al's findings of an increased HS/CS ratio in the
urine of children with CNSF and DMS. We also observed a
raised HS/CS ratio in some children with FSGS.
We found that the HSICS ratio correlated strongly with
albuminuria. It might be that increased losses of HS from the
GBM leads to a greater degree of proteinuria as result of loss of
GBM anionic charge. Alternatively, a raised HSICS ratio might
be the non-specific consequence of high levels of proteinuria. It
might also be that the loss of HS in the urine is related to the
extent of structural damage of the glomeruli, which occurs to a
varying degree in the different forms of nephrotic syndrome in
which we found a raised HSICS ratio. However, it is not
possible on the basis of this study to explain these differences
nor their underlying mechanisms. Further studies are needed
Fig. 2. The urinaPy heparan suiphate/chondroitin
sulphate ratio in controls, CNSF, DMS, FSGS
and SSNS.
into degradation and synthesis of HS in the GBM in this group
of disorders.
We confirmed that children with SSNS have a normal urinary
HS/CS ratio. However, they had lower levels of proteinuria.
Selective proteinuria is unlikely to account for the low urinary
HS excretion seen in the SSNS group. In CNSF there is also
selective proteinuria [15], but they had the highest urinary HS
excretion. Most of the children in the SSNS group were on
steroids at the time of study. However, there was no significant
difference in the HS/CS ratios between those children on
steroids and those children off steroids.
In summary, we have shown that children with CNSF, DMS
and some children with FSGS, but not children with SSNS,
have an increased HS content in the urine compared to con-
trols. There was, however, a positive correlation of the HS/CS
ratio with Alb/Cr, suggesting that raised HS/CS ratios are
related to states of heavy albuminuria rather than characteristic
of specific histological categories.
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Fig. 3. The relationship between the urinaty albumin/
creatinine and heparan suiphate/creatinine ratio (r = 0.66,30 100 300 P < 0.0001). Symbols are: (•) CNSF; () DMS, (0)
FSGS; (*) SSNS.
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